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Biopharmaceutical classification of desloratadine – not all drugs 
are classified the easy way
The biopharmaceutical classification of drugs was designed 
as a basis for bio-waivers – a mechanism with the double 
ethical benefit of delivering new drug formulations to the 
market with less human testing and lower cost. However, 
many drugs defy simple classification because in vitro per-
meability and stability assessment can be challenging as 
shown in this study for desloratadine. Literature shows that 
desloratadine is highly soluble, while data on luminal stabil-
ity and permeability are circumstantial. Combined with 
borderline bioavailability and not really known fraction of 
absorbed dose, desloratadine was found to be a good exam-
ple for showing the innovative in vitro approaches necessary 
to unambiguously classify desloratadine according to Bio-
pharmaceutical Classification System (BCS) guideline. Pre-
sented study undoubtedly confirmed that desloratadine 
solubility is high and dissolution is very rapid for immediate 
release reference tablets. We have demonstrated deslorata-
dine stability under legally required conditions and also in 
more physiologically relevant media. High in vitro deslorata-
dine permeability was confirmed using Caco-2 and Parallel 
Artificial Membrane Permeability Assay (PAMPA). Well-es-
tablished in vitro model with rat intestinal tissue could not be 
used due to reasons elaborated in this paper.
Keywords: desloratadine, BCS-based bio-waiver, luminal 
stability, permeability, dissolution
A bio-waiver may be granted for immediate release formulations containing Biophar-
maceutical Drug Classification 1 and 3 drug candidates, which enable (very) rapid drug 
release and behave as stable, oral solutions in the gut.
Compared to other marketed antihistamines, desloratadine lacks several adverse effects, 
is less prone to drug-drug interactions, and exerts superior potency and selectivity for H1-
receptors (1). Following oral administration, the mean time to reach maximum plasma con-
centrations and elimination half-life are approximately 3 and 27 hours, respectively. Neither 
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absorption, desloratadine is subjected to extensive hepatic metabolism to active metabolite 
3-hydroxydesloratadine, which is subsequently inactivated by glucuronidation (4). Given 
that desloratadine is extensively metabolized, only 8 % of total plasma AUC corresponds 
to desloratadine, which is in line with very low amounts of unchanged drug detected in 
urine (< 2 %) and feces (< 7 %) (2, 5). The main plasma species are thus desloratadine 
metabolites (5). Desloratadine is also a P-glycoprotein (P-gp) substrate (5, 6); however, linear 
pharmacokinetics over a dosage range of 5–20 mg has been established in healthy volunteers 
(4), which suggest that the intestinal absorption is not limited by the active transport. The 
recommended dose is one 5 mg tablet once daily. Available literature suggests that deslo-
ratadine can be classified as BCS 1 substance (4, 7, 8), which would make formulations eli-
gible for waiving in vivo bioequivalence human studies if several conditions would be 
fulfilled based on the guidelines (9, 10). Namely, the formulations have to be immediate 
release solid oral dosage forms without excipients that can affect the rate or the extent of 
absorption (9, 10). For BCS 1 compounds, the formulation must enable fast dissolution over 
the pH range 1.2, 4.5, and 6.8 (≥ 85 % dissolved at 30 min). The drug must be highly soluble 
(i.e. the highest dose has to dissolve in 250 mL or less of aqueous media over pH range 1–6.8), 
and highly permeable (fraction of dose absorbed (Fabs) in humans ≥ 85 %). The applicant 
must further demonstrate drug stability in the intestinal environment by showing > 95 % 
recovery after 1 h incubation in simulated gastric fluid (SGF) and 3 h incubation in simu-
lated intestinal fluid (SIF), both at 37 °C. The eligibility for waiving in vivo human study 
also depends on the drug’s therapeutic index (9), which is not an issue for desloratadine, 
because it is not a drug with narrow-therapeutic range.
Based on the information for the reference product Aerius® (a 5 mg desloratadine im-
mediate release tablet), desloratadine solubility is high; reported solubility values in the 
literature are 39.7 mg mL–1 in 0.1 mol–1 HCl, 0.1 mg mL–1 in water, and 1.5 mg mL–1 in phos-
phate buffer pH 7.4 (11). Desloratadine permeability could also be designated as “high”, 
because the absorbed fraction of oral dose is more than 90 % (i.e. almost complete) in labo-
ratory animals and humans. Although mass balance studies suggest high permeability (i.e. 
Fabs > 90 %) (11, 12), approximately half of the 87.1 % of recovered metabolites were found in 
the urine and half in feces (13). This could raise the question regarding the origin of fecal 
metabolites, since they could be formed in the gut lumen prior to systemic absorption, 
making the estimation of a fraction of desloratadine absorbed much less reliable for the 
assessment of desloratadine permeability. The data on desloratadine ś permeability and 
gastrointestinal stability are thus still ambiguous and do not allow a simple BCS classifica-
tion. In cases when in vivo data are inconclusive, they should be complemented by care-
fully selected in vitro measurements and models. Therefore, the aim of the present study 
was to show BCS classification of desloratadine by following the guidelines for waiving in 




Acetonitrile, HPLC gradient grade and methanol (Ultra) HPLC gradient grade were 
purchased from JT Baker. Metoprolol tartrate and Lucifer Yellow (Sigma Aldrich Chemie, 
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Germany) and desloratadine USP reference standard were used. 85 % ortho-phosphoric 
acid and 25 % ammonia solution were purchased from Merck, Germany.
Caco-2 cells were obtained from National Collection of Type Cultures, Public Health 
England. Dulbecco’s modified Eagle’s medium (DMEM), heat-inactivated fetal bovine se-
rum (FBS), sodium pyruvate, non-essential amino acids solution, Hank’s balanced salt 
solution (HBSS), 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), TrypLETM 
Select were purchased from Life technologies (UK). Cell culture plate assemblies were 
purchased from Merck Millipore (IRL) and cell culture flasks were from Sarstedt (Ger-
many). 
Caco-2 culture
Caco-2 cells (ECACC, 09042001, Lot No. 09E012, passage number 47, STR verification: 
09/06/2009, PCR based mycoplasma detection: 12/06/2009, routine mycoplasma detection with 
MycoAlert™ Mycoplasma Detection Kit (Lonza)) were maintained between passages 51–57 
at 37 °C, 5 % CO2 and 95 % relative humidity. Cells were grown in DMEM supplemented 
with 10 % FBS, 1 % sodium pyruvate and 1 % non-essential amino acids. After reaching ap-
proximately 90 % confluence in 75 cm2 cell culture flasks, they were detached with TrypLETM 
Select and plated onto polyethylene terephthalate (PET) membranes (1 µm pores, 0.7 cm2, 
Millipore) in 24-well cell culture plates at a density of 1 × 105 cells cm–2. Cell culture medium 
was replaced by fresh medium 24 h post-seeding and then every 2–3 days (400 µL apical, 800 
µL basolateral wells). It was also replaced 24 h before the permeability assay.
Desloratadine solubility
Reported desloratadine pKa values are 4.4 and 10.0 (14). By using the shake flask method, 
saturated desloratadine solubilities were determined at 37 °C after 24 h incubation in water, 
0.1 mol L–1 HCl, acetate buffer pH 4.5, and in phosphate buffer pH 6.8. The experiments 
were carried out in triplicate; average values and accompanied RSD values (expressed in 
%) are presented in Table I.
Dissolution of reference samples
Dissolution studies for 5 mg immediate release reference tablets (Merck, Clarinex, US 
market) were performed with Apparatus 1 at 100 rpm in 500 mL of 0.1 mol L–1 HCl, acetate 
Table I. Equilibrium desloratadine solubility at 37 °C in different media. An average equilibrium solubility and 
RSD values (expressed in %) of three measurements are presented in parentheses
Media Equilibrium solubility (mg mL–1) and RSD
Volume of media needed to 
dissolve 5 mg dose (mL)
0.1 mol L–1 HCl 40.49 (0.4 %) 0.123 
Acetate buffer pH 4.5 10.65 (1.4 %) 0.469
Sodium phosphate buffer pH 6.8 2.46 (1.2 %) 2.03
Water 0.92 (3.4 %) 5.43
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buffer pH 4.5, and in phosphate buffer pH 6.8 (9, 10). Apparatus 2 was also considered but 
it was not used due to coning (Fig. 1). Samples were analysed by UV quantification at 283 
nm wavelength. Six tablets per sample were analyzed.
Testing desloratadine luminal stability
Desloratadine stability in SGF, SGF with pepsin (SGFpep) and in SIF was tested. Buffers 
were prepared according to USP. Desloratadine stock solution (1 mg mL–1 concentration) 
was prepared in buffer pH 7.4 used for Parallel Artificial Membrane Permeability Assay 
(PAMPA) and 5 mL were added to 245 mL of SGF, SGF with pepsin, and SIF and were left 
at 100 rpm in dissolution vessel at 37 °C. Samples were withdrawn after 1 h (for SGF, SGFpep) 
and 3 h (for SIF), respectively, filtered through 0.45 µm PVDF and analyzed on UPLC. The 
test was carried out in duplicate and average values are reported in the result section.
PAMPA experiments
GentestTM pre-coated PAMPA plates were used according to manufacturer instructions. 
Prior to use, the PAMPA plate was warmed to room temperature. Buffers for PAMPA solu-
tions were McIlvaine buffers (pH 5.6, 6.8, and 7.4), prepared from 0.2 mol L–1 Na2PO4 × 2H2O 
and 0.1 Mol L-1 citric acid in defined volumetric ratios (15). Donor solution contained des-
loratadine (0.05 mg mL–1) and metoprolol (0.02 mg mL–1), and were added on donor (bottom) 
side. Different pH values of donor solutions were tested. The permeation of both drugs into 
McIlvaine acceptor buffer pH 7.4 was determined after 3 h incubation at 37 °C by UPLC. 


























( ) ( )D D A A
D A







Fig. 1. The impact of dissolution apparatus selection and agitation speed on desloratadine release in 
sodium phosphate buffer pH 6.8. Average data is shown (6 tablets were analyzed for each condition).
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where Papp is apparent permeability coefficient (cm s–1), Aeq is concentration in the donor 
well plate at the beginning of the experiment, AD(t) is the concentration of the donor well 
sample after 3 h incubation period, AA(t) is the concentration of the acceptor well sample 
after 3 h incubation, VD is the donor well volume, VA is the acceptor well volume, S is filter 
area, and t is incubation time.
In vitro permeability through Caco-2 experiment
Caco-2 cells were seeded and cultured on porous membranes as described above. 
After three weeks, the cell culture medium was removed. Caco-2 monolayers were rinsed 
three times with buffer solution (HBSS with 0.01 mol L–1 HEPES), pre-warmed to 37 °C and 
transepithelial electrical resistance (TEER) was determined. Only monolayers exhibiting 
TEER values ≥ 800 W cm2 were used.
Desloratadine, metoprolol and Lucifer Yellow solutions were prepared in pH 7.4 buffer 
(HBSS with 0.01 mol L–1 HEPES). Donor concentrations used were 5 mg desloratadine/250 
mL (≈ 65 mM), 100 mg metoprolol/250 mL (≈ 1.4 mmol L–1 concentration) and 20 mmol L–1 
Lucifer Yellow.
The permeability of each drug substance was tested in both directions; apical to baso-
lateral (AP-BL) and basolateral to apical (BL-AP). For AP to BL direction, 400 µL of test solu-
tions were added to the apical side of monolayers and 800 µL of buffer solution to each 
acceptor well. When tested BL-AP direction, 800 µL of test solutions and 400 µL of buffer 
solution were added to the basolateral and apical wells, respectively. Samples were with-
drawn from the receiver wells at 30, 60, 90, 120 and 180 min and from the donor wells at 0, 
90 and 180 min. The volume withdrawn was replaced with fresh buffer or donor solution. 
Following sample collection, the TEER values were determined and then the monolayers 
were rinsed with buffer and incubated the second time with 20 µM Lucifer Yellow solution 
for 60 min. Fluorescence for 100 µL aliquots withdrawn from the receiver wells was read 
using the Infinite M1000 reader (Tecan, Switzerland) (Ex: 430 nm, Em: 540 nm).
For the assessment of desloratadine and metoprolol permeability, only those Caco-2 
cell monolayers that retained acceptable monolayer integrity were used; TEER at the end 
of permeability tests ≥ 500 W cm2 and Lucifer Yellow permeability ≤ 10.0 × 10–7 cm s–1.












where  (mmol s–1 or mg s–1) is the total amount of investigated drug substance transported 
to the acceptor side per unit time,  is the exposed surface area of the cell monolayer (0.7 cm2), 
(mol L–1 or mg mL–1) is the average initial concentration of drug substance in donor wells.












where  is the apparent permeability coefficient of drug substance in BL to AP direction and 
is the apparent permeability coefficient of the same drug substance in AP to BL direction.
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In vitro permeability through rat jejunum
The experiments conform to the law for the protection of animals (Republic of Slovenia) 
and are registered at the Veterinary Administration of the Republic of Slovenia. Jejunum from 
male Sprague-Dawley rats (250–320 g) was obtained after 18 h without food and water ad li-
bidum followed by decapitation. It was prepared and mounted in Easy Mount side-by-side 
diffusion chambers (Physiologic Instruments, San Diego, CA, USA) as previously described 
(16). Ringer buffer of pH 7.0 and 7.4 were used on donor/mucosal and acceptor/serosal sides, 
respectively. Throughout the experiments, Ringer solutions on both sides of the jejunum were 
continuously bubbled with carbogen (95:5, O2/CO2). To sustain tissue viability, 10 mM d-glu-
cose and 4 % human serum were present on the serosal side, and 10 mmol L–1 d-mannitol on 
the mucosal side to assure adequate osmolarity. During a 2 h experiment, tissue was incu-
bated at 37 °C and acceptor solutions were sampled every 20 min. The withdrawn volume 
was replaced by fresh 10 mmol L–1 d-glucose Ringer buffer pH 7.4 with 4 % human serum. 
The withdrawn acceptor samples were used to determine the permeability of desloratadine.
Tissue viability and integrity during the experiment were controlled by monitoring 
the trans-tissue potential difference, the short circuit current and trans-tissue electrical 
resistance with a multichannel voltage-current clamp. At the end of the permeability ex-
periment, a decrease of trans-tissue potential difference after the addition of 100 µL of 625 
mmol L–1 D-glucose had been recorded and used to assess tissue viability and adequacy of 
active transporters. The permeability of FITC dextran was used for the determination of 
paracellular tight-junction integrity (17).
Desloratadine retention in rat intestinal rings
Intestinal jejunum was obtained as mentioned in “In vitro permeability through rat 
intestine”. Intestinal rings were weighed (720 mg wet weight of intestinal rings was used) 
and incubated at 37 °C in 7.5 mL of carbonated Ringer buffer pH 7.4, supplemented with 10 
mmol L–1 d-glucose and desloratadine (0.02 mg mL–1). Samples were withdrawn after 1 and 
2 h, and at the end, the tissue was homogenized and desloratadine entrapped by the tissue 
was extracted during protein precipitation with ice-cold acetonitrile (tissue/acetonitrile = 
1:3) for 24 h. After centrifugation at 4 °C and 10000×g for 10 min the amount of desloratadine 
in the supernatant was determined by HPLC.
UPLC method – quantification of desloratadine and metoprolol for Caco-2 in vitro 
experiment
For the quantification of desloratadine and metoprolol in the acceptor and donor solu-
tion obtained in Caco-2 permeability experiments, a Kinetex C18 (2.6 mm × 50 mm) column 
at 40 °C was used. Gradient method was used with the organic component of the mobile 
phase increasing from 4 % at 0–1 min to 45 % at 3.5 min with the end of analysis at 4 min. 
10 µL of samples were injected and the absorbance was detected at 220 nm. Samples in the 
autosampler were kept at 10 °C.
HPLC method
For desloratadine quantification after the uptake into intestinal rings and extraction 
from the tissue, the Agilent 1100 system (degasser, binary pump, well-plate sampler, column 
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thermostat and DAD) was used with the Waters XTerra MS C18 column (3.5 µm particles; 
4.6 × 100 mm) at 45 °C. The flow of the mobile phase (77 % of 0.5 % ammonium phosphate 
pH = 3.0 and 23 % of acetonitrile) was 1.5 mL min–1. The detection was made at 276 nm. The 
autosampler temperature was 10 °C and the injected sample volume was 10 µL.
Sample analysis by liquid chromatography with tandem mass spectrometry (LC-MS/MS)
The permeability samples were prepared by protein precipitation using a threefold 
volume of acetonitrile and brief 10 min centrifugation at 15000×g. The samples (1.0 µL) were 
injected onto the Agilent 1290 Infinity liquid chromatograph coupled with the 6460 Triple 
Quadrupole detector (Agilent Technologies, Santa Clara, USA) equipped with the Jet-
Stream™ electrospray. The chromatographic separation was performed on the Kinetex 
column C18 50 × 2.1 mm, with 2.6 µm particles (Phenomenex, Torrance, USA) maintained 
at 40 °C and using a linear gradient elution with a flow rate of 0.65 mL min–1 of the mobile 
phase consisting of 0.1 % formic acid in water (mobile phase A) and 100 % acetonitrile 
(mobile phase B) with the following gradient steps (min, % B): (0.0, 2), (0.25, 2), (0.5, 15), (1.00, 
35), (1.25, 45), (1.50–1.80, 55), (2.00–3.00, 2). The total run time including re-equilibration was 
3.0 min. The mass spectrometer was operated in positive mode using the following ion 
source parameters: gas flow (and temperature): 5 L min–1 (275 °C), nebulizer pressure: 45 
psi, sheath gas flow (and temperature): 11 L min–1 (320 °C) and the capillary voltage was 
4000 V. The fragmentor voltage was 181 V. Both quadrupoles were set at the widest mass 
resolution (2.5 amu) with the following m/z transitions: 311.1 → 259.1 at 17 eV and 311.1 → 
243.1 at 53 eV for quantifier and qualifier ion of desloratadine, respectively. The qualifier/
quantifier ratio was 37 %. Haloperidol was used as an internal standard with the final 
concentration in each sample of 45 µg L–1 and quantitated with the m/z transition 376 →165 
at 24 eV collision energy with unit resolution. The method was checked for selectivity (Fig. 
Fig. 2. A typical chromatogram of desloratadine obtained with liquid chromatography with tandem 
mass spectrometry (LC-MS/MS).
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2), working range, accuracy, precision, and matrix effect. The linear range was confirmed 
over the concentration interval between 0.325 and 8000 µg L–1; however, due to the observed 
lower-than-anticipated test sample concentrations, the calibration range was narrowed 
down to 0.325–2000 µg L–1 with good accuracy (bias < 10 %) and injection precision (< 10 % 
RSD) using the weighted (1/c2) linear regression. The limit of quantitation was demon-
strated to be 0.325 µg L–1 based on accuracy, precision and signal-to-noise ratio criterion 
(area, peak-to-peak) (Fig. 2). The signal abundance was checked after each 10 test samples 
and the uniformity and stability of the obtained responses indicated absence of any sig-
nificant matrix buildup from the tissue incubation medium causing signal deterioration as 
demonstrated by RSD values from test samples below 7.2 %. Furthermore, the signal drop 
due to the presence of matrix background from tissue incubation medium was only 4 % 
compared to the neat standard solution (determined in 8 parallels).
RESULTS AND DISCUSSION
Equilibrium desloratadine solubility
Equilibrium solubility results (Table I) show pH-dependent solubility. Regardless of 
the media used for solubility determinations, the entire desloratadine 5 mg dose was com-
pletely dissolved in 250 mL, demonstrating desloratadine as a highly soluble compound.
Dissolution of desloratadine immediate release formulations
To assess whether an immediate release formulation complies with the guidelines 
pertaining to drug release, dissolution in 500 mL of various dissolution media (0.1 mol L–1 
HCl, acetate buffer pH 4.5, or sodium phosphate buffer pH 6.8) should be performed using 
either Apparatus 2 at 50 rpm or Apparatus 1 at 100 rpm. Preliminary evaluations indicated 
that desloratadine release is obscured by coning (Fig. 1). Namely, increasing agitation speed 
improved desloratadine recoveries at 45 min considerably; recoveries increased from 75.7 
% released at 50 rpm to 96.1 % released at 75 rpm, or even 100.6 % released in Apparatus 1 
at 100 rpm. Therefore, to avoid coning and assure rugged dissolution method, Apparatus 
1 and 100 rpm was used to evaluate the release as per guideline.
Table II. The average of desloratadine released in 500 mL of media using Apparatus 1, 100 rpma
Time (min) 0.1 mol L–1 HCl Acetate buffer pH 4.5 Phosphate buffer pH 6.8
10 100.4 102.5 103.3
15 101.0 102.1 102.6
20 104.7 102.0 102.5
30 101.0 103.0 102.6
45 100.3 102.3 102.8
a Each test was performed on 6 units.
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Reference formulation was therefore analyzed in 500 mL using Apparatus 1, at 100 
rpm. Regardless of the media used formulation showed very fast desloratadine release 
(Table II).
Intraluminal stability
It had been previously published that the absorption of desloratadine is almost com-
plete, with Fabs > 90 % (11, 12). Ramnathan et al. (12) reported the recovery of 88 % of 14C-
desloratadine dose based on the metabolite recovery; 47 % metabolites were recovered in 
feces and 41 % in urine (13). Mass balance studies do not show whether the metabolites 
detected in the feces are formed before, during or after the intestinal absorption and thus 
fail to provide conclusive evidence of desloratadine high intestinal permeability (13).
To reliably classify desloratadine as highly permeable, one needs to show that the fecal 
part of metabolites was not formed from the parent drug in the gut lumen, but rather after 
the absorption (18). Therefore, potential instability or degradation in the gut lumen due to 
enzymatic and/or hydrolytic degradation should be excluded.
Desloratadine recoveries were analyzed according to the guidelines (9) and they were 
all well above the 95 % threshold value (102.6 % in SIF, 99.6 % in SGF and 101.1 % in SGF 
with pepsin). Based on these results, desloratadine can be considered stable in the intestinal 
environment at 37 °C for the designated incubation time.
Desloratadine stability was additionally evaluated in more complex, physiologically 
relevant media to further strengthen the conclusion of desloratadine luminal stability (see 
“Desloratadine retention in rat intestinal rings”).
PAMPA permeability
Metoprolol has been widely accepted as a high permeability marker with complete 
absorption from the intestine (17). If the permeability of concomitantly investigated com-
pound is similar or higher than that of metoprolol, one can safely assume that tested drug 
also belongs to a high permeability class (19). Based on Table III, desloratadine has pH-
dependent permeability with the highest permeability found at higher pH values, which 







permeability (×10–6 cm s–1)
Average METOPROLOL 
permeability (×10–6 cm s–1)
5.5 7.4 1.13 (n = 8; RSD 32 %) 1.09 (n = 8; RSD 31 %)
6.8 7.4 7.81 (n = 8; RSD 17 %) 4.60 (n = 8; RSD 25 %)
7.4 7.4 16.6 (n = 8; RSD 9.7 %) 9.09 (n = 8; RSD 22 %)
5.5 5.5 5.74 (n = 7; RSD 27 %) 2.22 (n = 7; RSD 27 %)
6.8 6.8 14.9 (n = 8; RSD 8.0 %) 7.53 (n = 8; RSD 11 %)
a The number of measurements (n) for each condition and relative standard deviation (RSD, expressed in %) are 
shown in parentheses.
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is in line with its protonation under various pH conditions. Regardless of pH, desloratadine 
permeabilities are significantly higher than those of metoprolol, implying that desloratadine 
belongs to a highly permeable class.
Although PAMPA membranes have not gained legal recognition as broad as other 
available models (9, 10), they have been used successfully for determining rank-order per-
meability of different compounds (20). Because of PAMPA membrane limitations (i.e. they 
can only be used to assess the contribution of passive diffusion to compound’s permeabil-
ity), the assessment of desloratadine permeability was continued using more complex in 
vitro models such as rat intestine and Caco-2 cell monolayers, which are known to express 
functional P-gp (17).
Permeability measurements in side-by-side diffusion chambers with rat jejunum
The reliability and abundance of experience with this validated in-house model (17) 
made it a natural first choice for the in vitro classification of desloratadine permeability as 
well as for the evaluation of the mechanism of desloratadine intestinal absorption and, if 
relevant – elimination. Unfortunately, after following the experimental design described 
in the section “In vitro permeability through rat jejunum”, at the end of the in vitro perme-
ability experiment, we could not detect desloratadine in the acceptor solutions with UPLC 
method described in the appropriate section of this paper. Extremely low recoveries were 
established by LC-MS/MS, which were at levels inadequate for the calculation of permeabil-
ity coefficients. We confirmed that no significant metabolic processes converting deslorata-
dine to its known metabolites took place in the rat small intestinal tissue in vitro. The ex-
periment with intestinal rings described hereafter clarified the reasons for the inability of 
the Sweetana-Grass-type experiment to measure the permeability of desloratadine.
Desloratadine retention in rat intestinal rings
To exclude desloratadine loss owing to instability in carbonated Ringer buffer or ad-
sorption to plastics of side-by-side diffusion chambers for in vitro permeability experiments, 
desloratadine recoveries at 37 °C after 2 h incubation in carbonated Ringer buffer pH 7.4 
supplemented with 10 mM d-glucose were compared to the unexposed standard solution 
with the same starting donor concentration (5 mg/250 mL, solution kept at room tempera-
ture in the glassware).
Table IV. Desloratadine recoveries after 1 and 2 h incubation in carbonated Ringer buffer pH 7.4 supplemented 
with 10 mmol L–1 D-glucose compared to desloratadine standard solution (*), which were kept at room 
temperature and it was not carbonated
1 h 2 h
Unexposed standard solution in glassware (*), room temperature 100 % 99.1 %
Carbonated standard solution in glassware, 37 °C 100.4 % 101.3 %
Carbonated standard solution in side-by-side diffusion chambers, 37 °C 90.5 % 90.5 %
Carbonated standard solution incubated with intestinal rings, 37 °C 38.9 % 34.0 %
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The recoveries of desloratadine incubated with intestinal tissue were also assessed and 
tissue extraction was performed (Table IV). Data showed that desloratadine is stable in 
physiologically relevant Ringer buffer at 37 °C for the time needed to perform permeabil-
ity tests. Approximately 10 % loss of drug was noted during the incubation of solution in 
side-by-side diffusion cells, indicating minor drug adsorption to the plastic surface. How-
ever, this loss was too small to explain our inability to quantify desloratadine after in vitro 
permeability test in the acceptor solution. On the other hand, a significant decrease of 
desloratadine concentration was noted, when the standard solution was incubated with 
intestinal rings, indicating a high affinity of desloratadine for the tissue. Extraction of in-
testinal rings after 2 h incubation proved our hypothesis, since approximately 50 % of the 
initial donor desloratadine dose (5 mg/ 250 mL) was retained by the tissue.
In vitro permeability of desloratadine through Caco-2 monolayers
Permeability of desloratadine was determined through Caco-2 cell monolayers con-
comitantly with a highly permeable marker metoprolol. Only those cell inserts, which re-
tained suitable monolayer integrity until the end of experiments, were considered as as-
sessed by TEER values and Lucifer Yellow permeability. The average TEER values before 
the start of in vitro permeability test were 1338 W cm2 (AP-BL direction) and 1202 W cm2 
(BL-AP direction), respectively. After the experiments, average TEER values were 706 W 
cm2 (AP-BL direction) and 847 W cm2 (BL-AP direction), while average Lucifer Yellow per-
meabilities were 4.87 × 10–7 cm s–1 (AP-BL direction) and 4.73 × 10–7 cm s–1 (BL-AP direction), 
respectively.
Desloratadine permeability in AP-BL direction (9.54 × 10–6 cm s–1) was similar to the 
metoprolol permeability (9.43 × 10–6 cm s–1) in the same direction; therefore, desloratadine 
can be considered highly permeable. Although desloratadine permeability in BL-AP direc-
tion was slightly higher (16.7 × 10–6 cm s–1) than the one in the opposite direction, the efflux 
ratio (i.e. the ratio between average BL-AP and AP-BL permeability) was approximately 1.7. 
BCS based guidelines (10) suggest that all efflux ratios below 2 are not considered relevant 
and the drug is not subjected to significant active transport in vivo. In the case of deslorata-
dine, the in vivo pharmacokinetic data states linear pharmacokinetics over a dose range of 
5–20 mg. This means that potential active transport in the intestine does not have any 
significant role in limiting desloratadine absorption. This is in line with our permeability 
data, since the efflux ratio is well below 2 even when measured by an in vitro model, which 
is known to over-express P-gp efflux transporter (21).
For ethical and economic reasons the BCS based biowaiver guidelines (9, 10) allow 
waiving the in vivo bioequivalence studies, if the in vitro surrogate tests demonstrate that 
two immediate-release (IR) drug products exert rapid dissolution under all luminal condi-
tions. Biowaiver approach is eligible only for those BCS1 and BCS3 compounds that are 
known to be stable inside the gastrointestinal milieu and do not belong to narrow thera-
peutic index drugs (10). While the demonstration of high solubility, sufficient intestinal 
drug stability and rapid dissolution of IR formulation is a straightforward approach with 
well-defined in vitro conditions, the assessment of permeability may be a daunting under-
take. The major agencies agree that a high permeability classification is justified when the 
fraction of the drug absorbed in humans exceeds 85 % as can be shown with bioavailability 
data and/or mass balance studies. Several methodologies are considered for providing sup-
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porting information (in vivo intestinal perfusion in humans, in vivo or in situ intestinal 
perfusion studies on animals, in vitro permeation studies through excised human or animal 
intestinal segments, and in vitro permeation studies on cultured cells), if the permeability 
model used is adequately characterized to show its suitability for the intended purpose. 
Since data on human intestinal permeability is limited (22), using other available models 
to assess drug permeability seems inevitable. As the case of desloratadine was laid down 
in the “Introduction”, the available data indicates that this drug could be a BCS 1 substance. 
While only one reference (11) mentions ≥ 90 % of absorbed dose, other data are inconclusive. 
Namely, a mass balance study, which reported at least 88 % of drug absorbed, is based on 
metabolite recovery in urine and feces. The recovery of desloratadine determined for the 
fecal part, unfortunately, could point to drug instability in the gastrointestinal tract prior 
to the intestinal absorption.
Therefore, to check whether desloratadine could indeed be a BCS 1 candidate, in vitro 
evaluations according to BCS based biowaiver guidelines were performed (9, 10) and sup-
ported with additional testing to verify their validity. The high solubility of 5 mg deslo-
ratadine dose was demonstrated, as well as very fast dissolution of the reference IR tablet. 
Further, desloratadine incubation in SGF with and without pepsin, and in SIF indicated ≥ 
95 % recovery, which confirms adequate desloratadine luminal stability. This disambigu-
ates the in vivo human metabolite recovery data, which was probably a critical issue of 
biowaiver applicability to desloratadine. Namely, the metabolites from the fecal fraction 
are indeed formed after the drug has been absorbed from the intestine, therefore the frac-
tion of desloratadine dose absorbed must be at least 88 % (13). Desloratadine stability in 
this paper was additionally shown in more physiologically relevant media (i.e. carbonated 
Ringer buffer pH 7.0 supplemented with glucose at 37 °C for 2 h) because during our initial 
attempt to determine desloratadine intestinal permeability using a validated permeability 
model, i.e. excised rat jejunum mounted in side-by-side diffusion cells (17), turned out to 
be an unsuccessful attempt. Namely, no drug could be quantified in the acceptor solution, 
although the measurements with PAMPA membranes indicated high desloratadine passive 
permeability comparable to that of metoprolol, which is a known high permeability stan-
dard (9). The in-depth investigation has shown an extensive desloratadine retention by the 
tissue (i.e. more than half of the administered dose), when rat intestinal segments were 
used. Desloratadine permeability was therefore measured through Caco-2 cell monolayers. 
This is also a suggested model in the BCS biowaiver guidelines (9), but it is structurally 
less complex, which was an advantage because of less biological material available for 
nonspecific binding. This cell line originates from human colorectal adenocarcinoma cells 
and resembles native human enterocytes to some, limited extent (23). Because Caco-2 mono-
layer constitutes only a single-cell-thick barrier compared to the full-thickness intestinal 
wall of the rat jejunum, the unspecific retention of desloratadine by Caco-2 cells was indeed 
lower. It was low enough to enable reliable desloratadine quantification in the acceptor 
solution and the determination of apparent permeability coefficients. By using this model, 
we were able to determine desloratadine permeability compared to the highly permeable 
internal standard metoprolol. This data was further supported by a non-biological in vitro 
assay with artificial membranes – the PAMPA test. It is also of relevance that the intestinal 
active transport of desloratadine, which can only be established in vitro, was shown to be 
low and therefore of no relevance for desloratadine biopharmaceutical classification. With 
all these information now available, combined with the solubility, dissolution and in vivo 
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absorption data known previously and confirmed within this paper one should conclude 
that desloratadine is a good biowaiver candidate.
CONCLUSIONS
While the ethical and economical reasoning for expanding the number biowaivers are 
obvious, the complexity of drug absorption too often does not allow a simple justification 
of a biowaiver based solely on available in vivo pharmacokinetic data. As aimed, the pre-
sented paper shows the usefulness of well-established in vitro methods for biopharmaceu-
tical drug classification in cases when the in vivo data alone are inconclusive. While setbacks 
are possible, as it was also demonstrated within the presented example, they can be over-
come by a rational choice of methods. We believe that the classification of desloratadine as 
a BCS 1 class drug which is chemically and metabolically stable in the gut lumen has been 
confirmed. It would, therefore, be ethically preferable to register new.
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